Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$4.81 - $15.38 $12.2 Million - $38.9 Million
2,530,000 Added 413.35%
3,142,079 $46.8 Million
Q4 2022

Feb 14, 2023

SELL
$9.51 - $12.95 $951,000 - $1.3 Million
-100,000 Reduced 14.04%
612,079 $6.9 Million
Q1 2022

May 16, 2022

SELL
$13.65 - $22.06 $682,500 - $1.1 Million
-50,000 Reduced 6.56%
712,079 $12 Million
Q4 2021

Feb 14, 2022

SELL
$21.49 - $74.4 $5.37 Million - $18.6 Million
-250,000 Reduced 24.7%
762,079 $16.4 Million
Q3 2021

Nov 15, 2021

BUY
$52.51 - $80.91 $6.44 Million - $9.92 Million
122,625 Added 13.79%
1,012,079 $74.8 Million
Q2 2021

Aug 16, 2021

BUY
$52.2 - $75.23 $401,104 - $578,067
7,684 Added 0.87%
889,454 $48.6 Million
Q4 2020

Feb 16, 2021

SELL
$34.11 - $112.26 $3.07 Million - $10.1 Million
-90,000 Reduced 9.26%
881,770 $76 Million
Q3 2020

Nov 16, 2020

BUY
$29.36 - $47.1 $28.5 Million - $45.8 Million
971,770 New
971,770 $36 Million

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $74.6M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.